Subjects with nonalcoholic fatty liver disease (NAFLD) NAFLD
Conditions
Interventions
Biofit 1 tab oral twice a day for 12 weeks,Placebo 1 tab oral twice a day for 12 weeks
Experimental Drug,Placebo Comparator Drug
Probiotic arm,Placebo
Sponsors
Bhumibol Adulyadej Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Subjects with nonalcoholic fatty liver disease diagnosed by Fibroscan or liver biopsy
Exclusion criteria
Exclusion criteria: 1. Subjects with a history of diagnosed chronic hepatitis B or chronic hepatitis C 2. Subjects diagnosed with autoimmune hepatitis. 3. Subjects diagnosed with liver cancer 4. Subjects diagnosed with hereditary liver disease. 5. Subjects who consume more than 30 grams of alcohol per day for men or more than 20 grams per day for women over 10 years, 6. Subjects taking herbal medicine or narcotic drugs suspected of causing hepatitis, 7. Subjects who have taken antibiotics, probiotics, or medications known to affect the liver within 6 months before the start of the study and during the study, 8. Subjects diagnosed with bile duct disease. 9. Pregnant women. breastfeeding women, and subjects with soybean allergies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of liver steatosis and fibrosis 12 weeks Controlled Attenuation Parameter score and liver stiffness measure | — |
Secondary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase 12 weeks International unit | — |
Countries
Thailand
Contacts
Public ContactChanunta Hongthanakorn
Bhumibol Adueyadej Hospital
Outcome results
None listed